LIFEVANTAGE CORP Loss on Contract Termination
LIFEVANTAGE CORP (LFVN) reported Loss on Contract Termination of $400.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Notes
us-gaap:LossOnContractTermination · last filed 2024-05-02
- LIFEVANTAGE CORP loss on contract termination for the quarter ending 2023-03-31 was $400.00K.
- LIFEVANTAGE CORP loss on contract termination for the quarter ending 2022-12-31 was $400.00K.
| Period end | Loss on Contract Termination 3 month | Loss on Contract Termination 6 month | Loss on Contract Termination 9 month |
|---|---|---|---|
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-02 | $400.00K 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $400.00K 10-Q · filed 2024-01-30 | $400.00K 10-Q · filed 2024-01-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |